GLMD
Galmed Pharmaceuticals LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.75M
P/E Ratio
—
EPS
$-2.39
Beta
0.42
52W High
$2.34
52W Low
$0.41
50-Day MA
$0.62
200-Day MA
$1.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment of liver diseases. The company is headquartered in Tel Aviv, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-8.43M |
| Operating Margin | 0.00% |
| Return on Equity | -64.20% |
| Return on Assets | -28.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.49 |
| Price-to-Book | 0.23 |
| Price-to-Sales (TTM) | 61.38 |
| EV/Revenue | 6.09 |
| EV/EBITDA | 0.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $6.58M |
| Float | $6.37M |
| % Insiders | 0.99% |
| % Institutions | 3.38% |
Data last updated: 4/8/2026